1-(2-Imidazolin-2-yl)-2-pyrrolidone (9).—2-(3-Carboxypropylamino)-2-imidazoline (33.7 g) was esterified according to the procedure described for 2, and the ester HCl (33.7 g, oil) was treated with a solution of 7.9 g of NaOMe in 150 ml of MeOH. The NaCl was removed by filtration and the filtrate was evaporated to dryness. The solid residue was extracted with PrOH in a Soxhlet extractor. The PrOH solution was concentrated to about 80 ml, Et₂O was added to cloud point, and the mixture was chilled to obtain 9.73 g of product, mp 107.5–109°. Anal. (C₇H₁₁N₈O) C, H, N.

Acknowledgment.—The authors are grateful to Mr. P. Reisberg for the nmr spectrum and to Mr. William J. Bowling for technical assistance.

Potential Antidiabetics. Benzimidazole-2sulfonylglycamide Derivatives

S. M. DESHPANDE, K. C. DATTA,

Organic Division, Department of Chemistry, Faculty of Science

A. K. SANYAL, AND M. K. RAINA

Department of Pharmacology, College of Medical Sciences, Banaras Hindu University, Varanasi-5, India

Received July 25, 1969

Benzimidazole derivatives of type **1** where $R_1 = H$, Me, Et, and *n*-Pr, and $R_2 = CH_3C_6H_4SO_2$, $C_{10}H_7SO_2$, etc., are reported to possess hypoglycemic activity.¹⁻³ These compounds when compared with chloropropamide, tolbutamide, etc., indicate that an aromatic nucleus (homocyclic or heterocyclic) carrying a side chain $-SO_2NHCONRR'$ plays an important role in the pro-

TABLE I

No.	R	Mp, ^a °C	${f Recrystn}$	Yield, %	$Formula^b$
1	C_6H_{\flat}	147	Α	65	$\mathrm{C_{15}H_{16}N_4O_4S}$
2	CH_3	186	Α	35	$C_{10}H_{12}N_4O_3S$
3	C_2H_5	150 - 151	в	46	$\mathrm{C}_{11}\mathrm{H}_{14}\mathrm{N}_{4}\mathrm{O}_{3}\mathrm{S}$
4	$n-C_3H_7$	192	Α	38	$\mathrm{C_{12}H_{16}N_4O_3S}$
5	n-C ₄ H ₉	220 - 222	Α	42	$C_{13}H_{20}N_4O_4S$

^a Melting points were taken in open capillaries in sulfuric acid bath and are uncorrected. ^b Analyses for C, H, N were within $\pm 0.4\%$ of the theoretical values. ^cA = EtOH, B = dilute EtOH.

duction of potent antidiabetic drugs. The basic moiety seen in benzimidazoles (as is shown within block lines 1) coupled with the high antidiabetic activity exhibited by benzimidazole² prompted us to synthesize possible hypoglycemic agents derived from in the benzimidazole series (2) see Table I).



Experimental Section

2-Benzimidazolesulfonyl Chloride.—2-Mercaptobenzimidazole³ (20 g) in 800 ml of 20% AcOH was cooled in an ice bath and Cl_2 was passed first slowly then vigorously for 50-55 min.⁴ The product was filtered quickly.

Benzimidazole-2-sulfonylglycine.—The acid chloride was added immediately to a solution containing 10 g of glycine and 450 ml of 10% NaOH solution. The solution was stirred vigorously and was kept at room temperature overnight to complete the reaction. It was filtered and the filtrate was acidified to pH 2 with dilute HCl when sulfonylglycine precipitated. It was filtered, washed (cold H₂O), and collected; mp 214°.

Benzimidazole-2-sulfonylglycamide.—A mixture of 1 mole of the above sulfonylglycine and slightly more than 1 mole of alkyl- or arylamines was refluxed for 1-2 hr. When cooled the mixture was washed (5% Na₂CO₃ solution, 5% HCl, H₂O).

Pharmacology.—The compounds were studied for their hypoglycemic action in albino rats of either sex weighing 150-200 g, fasted for 18 hr (water was allowed *ad lib*). The blood sugar was determined by collecting blood (0.1 ml) from the tail of the rats and determined by the method of Folin and Wu.⁵

A suspension of 250 mg/kg of the test compounds in gum acacia was administered orally to six groups of rats. The blood sugar was determined after 3, 6, and 24 hr. At the end of 6 hr food weighed in grams was given to all of the rats and 18-hr blood sugar was again determined, *i.e.*, 24 hr after the drug administration. All of the test drugs and the reference drug, tolbutamide, were administered at 250 mg/kg (see Table II).

Compounds 1-3 and 5 have no significant hypoglycemic action; compound 4 at the doses tested reduced the blood sugar signifi-

	TABLE II						
	BLOOD SUGAR DETERMINATION						
1 1							

		D1001	DOUGAR DETERMINATION		
Test compd	No. of animals	Initial blood sugar, mg/100 ml	3 hr 6 hr 24 hr		
Control	5	101.94 ± 5.2^{a}	98.68 ± 5.2	97.54 ± 5.1	105.5 ± 1.4
1	5	104.40 ± 1.2	99.98 ± 1.6	98.22 ± 1.8	99.67 ± 1.6
2	5	103.50 ± 1.7	99.54 ± 1.8	98.32 ± 1.2	99.87 ± 1.4
3	$\overline{5}$	101.40 ± 1.9	98.74 ± 1.6	97.12 ± 1.09	99.46 ± 1.2
4	5	97.90 ± 2.1	90.04 ± 6.0	79.22 ± 2.01	95.86 ± 4.5
				(P < 0.001)	
5	5	107.62 ± 2.1	106.64 ± 3.1	116.60 ± 4.10	110.04 ± 2.01
Tolbutamide	5	94.51 ± 3.1	95.19 ± 6.2	59.56 ± 4.45	84.53 ± 2.2
				(P < 0.001)	

^{*a*} Mean \pm standard error.

S. S. Tiwary and A. Swaroop, J. Indian Chem. Soc., 39, 195 (1962).
 K. Okamoto, T. Taii, H. Koso, N. Takenaka, T. Hayakawa, and

T. Ibaraki, *Tohoku. J. Expl. Med.*, **61**, (Suppl 3), 36-61 (1955).
 (3) J. A. Van Allan and B. D. Deacon, "Organic Syntheses," Coll. Vol.

IV, John Wiley & Sons, Inc., New York, N. Y., 1963. p 569.

⁽⁴⁾ Richard O. Roblin, Jr., and James W. Clapp, J. Am. Chem. Soc., 72, 4890 (1950).

⁽⁵⁾ O. Folin and H. Wu, J. Biol. Chem., 41, 367 (1920).

Acknowledgment.—Thanks are due to the authorities of the Banaras Hindu University for providing the necessary facilities. One of the authors (K. C. D.) is grateful to C.S.I.R.. New Delhi, India, for a Junior Fellowship.

Conformational Aspects of Ureas in the Inhibition of the Hill Reaction^{1a}

MARVIN R. BOOTS,¹⁶ SHARON G. BOOTS,

School of Pharmacy, Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 23219

AND DONALD E. MORELAND

Crops Research Division, Agricultural Research Service U. S. Department of Agriculture, Crop Science Department, North Carolina State University, Raleigh, North Carolina 27607

Received August 15, 1969

In an earlier report² an effort was described to assess the conformational requirements of carbamate inhibitors of the Hill reaction. This study involves a similar approach which attempts to correlate the geometry of the ==NCONHPh moiety with inhibition of the Hill reaction. Two cyclic ureas (1, 2) with fixed con-



formations were synthesized and assayed. The corresponding linear ureas³ m-RC₆H₄NHCON(CH₃)₂ [R = H (3), R = Cl (4)] were also assayed so that a direct comparison could be made.

Chemistry.—Treatment of the appropriate isatoic anhydride with an aqueous solution of $MeNH_2$ gave the corresponding 2-amino-N-methylbenzamide (5). Reduction of 5 with diborane gave the corresponding 2amino-N-methylbenzylamine (6). Fusion of 6 with urea gave the desired cyclic ureas (1, 2).

The N,N-dimethylureido group, $(Me)_2NCONH$, is planar because of resonance and may exist in two possible conformations (A, B) depending on the position of the C=O group with respect to the amido hydrogen

$$CH_3)_2NCONHR \iff (CH_3)_2NCONHR$$

A, cis B, trans

atom. This suggests the possibility that one or both conformational forms could be involved in binding to a receptor. In attempting to assess this factor, two cyclic ureas (1, 2) which exist solely as the *cis* conformer were prepared and assayed. Compounds 1 and 2 were

(1) (a) Presented before the Division of Medicinal Chemistry, at the Southeastern Regional Meeting of the American Chemical Society, Richmond, Va., Nov, 1969. The investigations of D. E. Moreland were supported in part by Public Health Service Grant ES 00044. (b) To whom inquiries concerning this work should be addressed.

(2) M. R. Boots, J. Med. Chem., 12, 426 (1969).

(3) The linear ureas (3, 4) were supplied by E. I. duPont de Nemours and Company, Inc. Wilmington, Del.

inactive at $3 \times 10^{-4} M$, whereas I_{50} values of 1.5×10^{-5} and $2.7 \times 10^{-6} M$ were obtained for **3** and **4**, respectively. The inactivity of **1** and **2** may be attributed to the fact that the ureido group is in a conformation that prevents it from binding to the receptor. An alternative explanation involves the conformation of the Ph ring, which is restricted in the cyclic urea system. This restriction is not required in the linear ureas (**3**, **4**), and the Ph ring may assume a conformation that allows binding to the active site of the receptor.

Experimental Section⁴

2-Amino-N-methylbenzamide (5a).—The procedure of Clark and Wagner⁵ was modified. A solution of 40.8 g (0.25 mole) of isatoic anhydride, 100 ml (1.3 moles) of 40% aqueous MeNH₂, and 400 ml of H₂O was allowed to stand at 25° for 15 min. The mixture was extracted with EtOAc. The organic phase was washed (10% aqueous Na₂CO₃, H₂O, saturated aqueous NaCl) then dried (MgSO₄). The solvent was removed *in vacuo* to give 22.3 g (60%) of 5a, mp 77-79° (lit.⁶ mp 79-80°). 2-Amino-6-chloro-N-methylbenzamide (5b) was prepared

2-Amino-6-chloro-N-methylbenzamide (**5b**) was prepared analogously. The crude **5b** (27 g, 56%), mp 126–128°, was recrystallized twice from EtOAc-petroleum ether (60–75°) to afford an analytical specimen as white needles, mp 130–131°. *Anal.* (C₈H₉ClN₂O) C, H, N.

2-Amino-N-methylbenzylamine (**6a**).—To a mixture of 9 g (0.06 mole) of **5a** and 4.1 g (0.11 mole) of NaBH₄ in 90 ml of dimethoxyethane (DME) was added dropwise with stirring at 25° over a 1-hr period, 20.4 g (0.14 mole) of BF₃-Et₂O in 30 ml of DME. The mixture was stirred an additional 22 hr at 25°, then poured onto an ice-HCl mixture. It was extracted with Et₂O, then the acidic aqueous phase was made basic with NaOH solution and extracted with EtOAc. The organic phase was washed (H₂O, saturated aqueous NaCl), then dried (Na₂SO₄). The solvent was removed *in racuo* to afford 7.6 g of a liquid. Distillation yielded 4.5 g (55°) of **6a** as a colorless liquid, bp 116–118° (10 mm)(lit.⁷ bp 114–118° (10 mm)).

2-Amino-6-chloro-N-methylbenzylamine (**6b**) was prepared similarly. Crude **6b** was distilled to yield $2.2 \text{ g} (65^{\circ}_{\ell})$ of colorless liquid, bp 155–157° (10 mm). *Anal.* (C₃H₁₁ClN₂) C, H, N.

3-Methyl-3,4-dihydro-2(1H)-quinazolinone (1).—The procedures of Short and Swett⁸ and Martell and Frost⁹ were modified. A mixture of 0.60 g (4.4 mmoles) of **6a** and 0.53 g (8.8 mmoles) of urea was heated at 195° for 40 min. The resulting white mass was washed (H₂O), then dried to afford 0.55 g ($77\frac{\circ}{\epsilon}$) of a white solid (1), mp 198-205°. Three recrystallizations from EtOAc afforded an analytical specimen as white needles, mp 198-202°. *Anal.* (C₉H₁₀N₂O) C, H, N.

3-Methyl-5-chloro-3,4-dihydro-2(1H)-quinazolinone (2) was prepared similarly. Crude **2** (2.4 g, 92%), mp 195–200°, was recrystallized three times from EtOAc to afford an analytical specimen as white needles, mp 208–212°. *Anal.* (C₃H₃ClN₂O) C, H, N.

Biological Assays.—The molar concentration of the ureas required to reduce the photolytic activity of the isolated chloroplasts by $50C_{\ell}^{*}$ (I₃₀ value) was determined by previously described techniques,¹⁰ except that ferricyanide reduction was measured colorimetrically at 420 m μ following precipitation of chloroplast protein with trichloroacetic acid.

Determinations were performed in duplicate with three separate chloroplast extractions from Alaska pea leaves (*Pisum* sativum L.). Data are presented (see Introduction) as the arithmetic averages of the individual determinations.

⁽⁴⁾ Melting points, determined with a Thomas-Hoover capillary melting point apparatus, are uncorrected. Where analyses are indicated only by symbols of the elements, analytical results obtained for those elements were within $\pm 0.4\%$ of the theoretical values. Ir and nmr data of all the compounds were consistent with the proposed structures.

⁽⁵⁾ R. H. Clark and E. C. Wagner, J. Org. Chem., 9, 55 (1944).
(6) A. Weddige and M. Körner, J. Prakt. Chem., [2] 36, 141 (1887): Chem. Zentr., Zbl., 58, 1375 (1887).

 ⁽⁷⁾ A. R. Osborn and K. Schofield, J. Chem. Soc., 3977 (1956).

 ⁽¹⁾ A. R. Osborn and K. Schoneid, J. Chem. Soc., 5911 (1956).
 (8) J. H. Short and L. R. Swett, J. Org. Chem., 26, 3428 (1961).

⁽⁹⁾ A. E. Martell and A. E. Frost, J. Am. Chem. Soc., 72, 1032 (1950).

⁽¹⁰⁾ D. E. Moreland and K. L. Hill, J. Agr. Food Chem., 7, 832 (1959).